Document is current
Any future updates will be listed below
-
Authors
Kim, Won Kyum
Seong, Jae Young
Lee, Gyun Min
-
Funding
Funding for this research was provided by:
Ministry of Trade, Industry and Energy (Industrial Technology Innovation Program (10081300))
Korea Advanced Institute of Science and Technology
- License Information
-
More Information
Article History
Received: 12 May 2024
Revised: 20 August 2024
Accepted: 2 September 2024
First Online: 7 October 2024
Declarations
:
: The authors declare no conflict of interest.
: QuBEST BIO institutional animal care and use Committee (IACUC) reviewed the study protocol and approved it (QBIACUC-A19045, QBIACUC-A20099). Charles River Laboratories Evreux ethics committee (CEC) reviewed the study plan to assess compliance with Directive 2010/63/EU and French decree No. 2013–118. Independent institutional review board (IRB) reviewed and approved the clinical study protocol prior to beginning associated study procedures, and independent ethics committee (IEC), Advarra, an independent service provider (Ontario, Canada) reviewed the study. A no objection letter (NOL) from the Canadian authorities (Health Canada) dated 27-OCT-2021 (Control #: 257013) was received prior to the beginning of the study.
